VAXCHORA (Cholera Vaccine, Live, Oral)
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cholera (Disorder)
Conditions
Cholera (Disorder)
Trial Timeline
Jul 21, 2017 → Mar 6, 2020
NCT ID
NCT03220737About VAXCHORA (Cholera Vaccine, Live, Oral)
VAXCHORA (Cholera Vaccine, Live, Oral) is a approved stage product being developed by Bavarian Nordic for Cholera (Disorder). The current trial status is completed. This product is registered under clinical trial identifier NCT03220737. Target conditions include Cholera (Disorder).
What happened to similar drugs?
1 of 7 similar drugs in Cholera (Disorder) were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03220737 | Approved | Completed |
Competing Products
9 competing products in Cholera (Disorder)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 40 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 40 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Approved | 43 |
| Ciprofloxacin | Bayer | Phase 3 | 37 |
| PXVX0200 + placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 1 | 26 |
| PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol | Emergent BioSolutions | Phase 2 | 25 |